TLR7 signaling aggravates lung inflammation associated with increased anti-Scl-70 autoantibody production in murine bleomycin-induced systemic sclerosis - Report - MDSpire

TLR7 signaling aggravates lung inflammation associated with increased anti-Scl-70 autoantibody production in murine bleomycin-induced systemic sclerosis

  • By

  • Jefferson Fernandes Evangelista

  • Ana Karina Nisperuza Vidal

  • Donghua Xu

  • Mohammad Islamuddin

  • Yilin Chen

  • Chenxiao Wang

  • Raul Freitas

  • Shumei Liu

  • Elizabeth Engler-Chiurazzi

  • Robert V. Blair

  • Prasun K. Datta

  • Xuebin Qin

  • July 1, 2026

  • 0 min

Share

TLR7 Pathway Enhances Lung Inflammation in Murine Model of SSc

Overview

This study investigates the role of the TLR7-IRF7-IFN-I signaling pathway in systemic sclerosis (SSc) using a bleomycin-induced murine model. Findings indicate that TLR7 and IRF7 deficiency leads to reduced inflammation and autoantibody production.

Background

Systemic sclerosis (SSc) is a severe autoimmune disease associated with significant morbidity and mortality, particularly due to pulmonary complications. Understanding the mechanisms driving inflammation and fibrosis in SSc is crucial for developing effective treatments. The TLR7 pathway has been implicated in autoimmune responses, making it a relevant focus for research in SSc pathogenesis.

Data Highlights

ParameterTlr7−/− MiceIrf7−/− MiceWT Mice
Body Weight LossLessLessMore
Pulmonary InflammationReducedReducedIncreased
Anti-Scl-70 LevelsLowerLowerHigher

Key Findings

  • TLR7 and IRF7 deficiency resulted in less body weight loss in mice treated with bleomycin.
  • Reduced pulmonary interstitial inflammation was observed in Tlr7−/− and Irf7−/− mice.
  • Lower levels of anti-topoisomerase I autoantibodies were found in Tlr7−/− and Irf7−/− mice compared to wild-type mice.
  • Pharmacologic antagonism of CCR2 attenuated bleomycin-induced lung injury and dermal collagen deposition.
  • Type I interferon-related gene expression was lower in Tlr7−/− and Irf7−/− mice.

Clinical Implications

The findings highlight the role of the TLR7-IRF7-IFN-I signaling pathway in systemic sclerosis.

Conclusion

This study identifies the role of the TLR7 pathway in systemic sclerosis.

Related Resources & Content

  1. Clinical Rheumatology, 2024 -- Biomarkers Indicating Pathogenesis, Clinical Features, and Therapeutic Strategies in Systemic Sclerosis: A Comprehensive Review
  2. Frontiers in Immunology, 2026 -- Interleukin-10 at the crossroads of immunity in TLR7-induced lupus
  3. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease, 2026
  4. EULAR recommendations for the treatment of systemic sclerosis: 2023 update
  5. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease | New England Journal of Medicine, 2019
  6. Intensive Care Medicine — 21st Annual Congress of the European Society of Intensive Care Medicine
  7. Clinical Rheumatology — The Role of CAR-T Cell Therapy in Systemic Sclerosis Management
  8. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)
  9. EULAR recommendations for the treatment of systemic sclerosis: 2023 update
  10. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease | New England Journal of Medicine
  11. Frontiers | The immune landscape of systemic sclerosis: from pathogenic mechanisms to precision therapeutic breakthroughs

Original Source(s)

TLR7 signaling aggravates lung inflammation associated with increased anti-Scl-70 autoantibody production in murine bleomycin-induced systemic sclerosis

  • by Jefferson Fernandes Evangelista, Ana Karina Nisperuza Vidal, Donghua Xu, Mohammad Islamuddin, Yilin Chen, Chenxiao Wang, Raul Freitas, Shumei Liu, Elizabeth Engler-Chiurazzi, Robert V. Blair, Prasun K. Datta, Xuebin Qin

  • July 1, 2026

Related Content

Sensorimotor dysfunction and altered pain sensitivity in early hip osteoarthritis: associations with hip proprioception and balance impairment

Naringin and denosumab ameliorate osteoporosis and suppress the aldosterone-MR/SGK1 signaling axis by modulating the bone-kidney interorgan communication in Orchiectomized rats

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.